Astellas suffers pancreatic cancer failure with Vyloy Astellas' effort to expand the reach of its first-in-class claudin 18.2 drug Vyloy into pancreatic cancer has had a major setback.

#Astellas #pancreaticcancer #Vyloy #zolbetuximab #claudin182targetingcancerdrug #GLEAMstudy #metastaticpancreaticadenocarcinoma #GLEAMtrial #pancreaticcancerresearch #claudin182targetedtherapy #CLDN182testing #GanymedPharma #ESMO #GEJcancer #biopharma
zurl.co/DtTYd